Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
42 hedge funds and large institutions have $130M invested in Carisma Therapeutics in 2014 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 5 closing their positions.
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
8% more funds holding
Funds holding: 39 → 42 (+3)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 13
15% less capital invested
Capital invested by funds: $153M → $130M (-$22.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$1.67M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$1.34M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$659K |
| 4 |
Goldman Sachs
New York
|
+$200K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$197K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$2.52M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.47M |
| 3 |
TG
TCW Group
Los Angeles,
California
|
-$135K |
| 4 |
PAM
Paradigm Asset Management
New York
|
-$75.8K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$56.8K |
CARM Hedge Fund Activity: Q3 2014 in Review
42 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q3 2014, worth a combined $130M — down 15% from $153M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CARM positions and 5 closed out — a net gain of 3 holders — while 12 added to existing stakes and 13 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $1.67M. The largest seller was Franklin Resources, cutting an estimated $2.52M.
- 42 institutional investors held Carisma Therapeutics (CARM) as of Q3 2014, up from 39 in Q2 2014.
- Funds reported $130M of Carisma Therapeutics stock for Q3 2014, down 15% quarter-over-quarter.
- 8 funds opened new Carisma Therapeutics positions in Q3 2014 and 5 closed out, a net change of +3 holders.
- The largest Carisma Therapeutics buyer in Q3 2014 was JP Morgan Chase, an estimated $1.67M added.
- The largest Carisma Therapeutics seller in Q3 2014 was Franklin Resources, an estimated $2.52M sold.
Based on aggregated 13F filings for Q3 2014.